Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
2.780
-0.080 (-2.80%)
Nov 13, 2026, 4:00 PM EST - Market closed
Upstream Bio Revenue
Upstream Bio had revenue of $395.00K in the quarter ending September 30, 2026, a decrease of -42.17%. This brings the company's total for the last twelve months to $2.87M, up 2.54% year-over-year. In the year 2025, Upstream Bio had annual revenue of $2.85M with 20.42% growth. That makes Upstream Bio the 41,604th largest company in the world by revenue and 5,610th in the United States.
Revenue (ttm)
$2.87M
Revenue Growth
+2.54%
P/S Ratio
53.09
Revenue / Employee
$38,267
Employees
75
Market Cap
152.38M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.85M | 484.00K | 20.42% |
| Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
| Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
| Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
UPB News
- 4 days ago - Upstream Bio price target lowered to $18 from $36 at H.C. Wainwright - TheFly
- 5 days ago - Upstream Bio reports Q3 revenue $395,000, consensus $480,290 - TheFly
- 5 days ago - Upstream Bio Reports Third Quarter 2026 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 5 days ago - Upstream Bio Earnings release: Q3 2026 - Filings
- 5 days ago - Upstream Bio Quarterly report: Q3 2026 - Filings
- 7 weeks ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 2 months ago - Upstream Bio presents results from VALIANT trial at ERS Congress - TheFly
- 2 months ago - Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 - GlobeNewsWire